New AIDS drug shows 'phenomenal' results

Jan 02, 2007

AIDS researchers said a new drug shows promise for inhibiting the HIV virus in patients new to treatment or those currently taking a drug cocktail.

Clinical studies of the drug, called an integrase inhibitor, showed that, when combined with two existing drugs, it reduced the virus to undetectable levels in nearly 100 percent of HIV patients prescribed a drug regimen for the first time, The Los Angeles Times said Tuesday. It had a similar effect in 72 percent of salvage therapy patients, who take a mixture of existing medications aimed at stalling the virus until new drugs appear.

The drug essentially prevents the virus' DNA from integrating with a host's cells, inhibiting its ability to replicate itself.

The U.S. Food and Drug Administration should approve it in mid-2007. Manufacturer Merck & Co. is making it available sooner to patients in desperate straits.

"They tested it on some people who were in deep, deep salvage therapy, and even those people did remarkably well," Dr. Steven Deeks, a University of California, San Francisco salvage therapy authority, told the Times. "It seems to be a truly phenomenal drug that ... is changing the whole way we think about the management of these patients."

Copyright 2007 by United Press International

Explore further: Bacterial communities of female genital tract have impact on inflammation, HIV risk

Related Stories

Metabolic errors can spell doom for DNA

Jan 31, 2012

Many critical cell functions depend on a class of molecules called purines, which form half of the building blocks of DNA and RNA, and are a major component of the chemicals that store a cell’s energy. ...

A new approach to medicine

Sep 24, 2010

(PhysOrg.com) -- University of Connecticut researchers are exploring how to take a patient's own cells, re-engineer them, and replace them in the body.

Recommended for you

HIV reservoirs remain obstacles to cure

May 19, 2015

Antiretroviral therapy (ART) has proven lifesaving for people infected with HIV; however, the medications are a lifelong necessity for most HIV-infected individuals and present practical, logistical, economic ...

Microclinics help keep Kenyan HIV patients in care

May 18, 2015

A team led by researchers from UC San Francisco, Organic Health Response, and Microclinic International is reporting results of a study that showed significant benefits of microclinics—an innovative intervention ...

'Redesigned' antibodies may control HIV

May 18, 2015

With the help of a computer program called "Rosetta," researchers at Vanderbilt University have "redesigned" an antibody that has increased potency and can neutralize more strains of the AIDS-causing human ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.